CELERIS Trademark

Trademark Overview

On Thursday, April 29, 2021, a trademark application was filed for CELERIS with the United States Patent and Trademark Office. The USPTO has given the CELERIS trademark a serial number of 79322625. The federal status of this trademark filing is IR CANCELLED - US APPLICATION ABANDONED as of Friday, June 16, 2023. This trademark is owned by Celeris Therapeutics GmbH. The CELERIS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and technological services, namely, scientific research, analysis, and testing of molecules, proteins and drugs and other chemical substances, in the field of early phase of drug development in the chemical industry; scientific services, namely, identifying new drug compounds from analysis of molecules, proteins and drugs and other chemical substances; information technology consulting services for the chemical and pharmaceutical industries, as well as related industries, namely, cosmetics and the food industry; product quality testing, authentication and quality control for others in the chemical and pharmaceutical industries for drug, protein, food chemistry, cosmetics and materials science development
celeris

General Information

Serial Number79322625
Word MarkCELERIS
Filing DateThursday, April 29, 2021
Status402 - IR CANCELLED - US APPLICATION ABANDONED
Status DateFriday, June 16, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, October 4, 2022

Trademark Statements

Description of MarkThe mark consists of the word Celeris in black. To the left of the word is a broken circle design made of varying sized quadrilaterals in blue, pink and yellow.
Indication of Colors claimedThe color(s) black, blue, pink, and yellow is/are claimed as a feature of the mark.
Goods and ServicesScientific and technological services, namely, scientific research, analysis, and testing of molecules, proteins and drugs and other chemical substances, in the field of early phase of drug development in the chemical industry; scientific services, namely, identifying new drug compounds from analysis of molecules, proteins and drugs and other chemical substances; information technology consulting services for the chemical and pharmaceutical industries, as well as related industries, namely, cosmetics and the food industry; product quality testing, authentication and quality control for others in the chemical and pharmaceutical industries for drug, protein, food chemistry, cosmetics and materials science development

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code8 - Abandoned
Class Status DateTuesday, June 27, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCeleris Therapeutics GmbH
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressAT
Party NameCeleris Therapeutics GmbH
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressAT

Trademark Events

Event DateEvent Description
Wednesday, July 5, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Tuesday, July 4, 2023DEATH OF INTERNATIONAL REGISTRATION
Tuesday, July 4, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Monday, July 3, 2023DEATH OF INTERNATIONAL REGISTRATION
Monday, July 3, 2023NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Sunday, July 2, 2023DEATH OF INTERNATIONAL REGISTRATION
Tuesday, June 27, 2023ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
Tuesday, June 27, 2023ABANDONMENT - AFTER INTER PARTES DECISION
Tuesday, June 27, 2023OPPOSITION TERMINATED NO. 999999
Tuesday, June 27, 2023OPPOSITION DISMISSED NO. 999999
Tuesday, April 4, 2023NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Wednesday, March 15, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, March 15, 2023NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Tuesday, February 7, 2023REFUSAL PROCESSED BY IB
Friday, January 20, 2023OPPOSITION INSTITUTED NO. 999999
Wednesday, January 18, 2023OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Wednesday, January 18, 2023OPPOSITION NOTICE (IB REFUSAL) CREATED
Monday, October 31, 2022EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, October 4, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 4, 2022PUBLISHED FOR OPPOSITION
Monday, October 3, 2022NOTIFICATION PROCESSED BY IB
Wednesday, September 14, 2022NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 14, 2022NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, September 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, August 29, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 2, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, August 2, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, February 20, 2022REFUSAL PROCESSED BY IB
Thursday, February 3, 2022NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, February 2, 2022REFUSAL PROCESSED BY MPU
Wednesday, January 12, 2022NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, January 11, 2022NON-FINAL ACTION WRITTEN
Wednesday, December 29, 2021ASSIGNED TO EXAMINER
Tuesday, October 26, 2021APPLICATION FILING RECEIPT MAILED
Wednesday, October 20, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, October 14, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

celeris chemical drug industries scientific services namely pharmaceutical quality food development